Oncogenic KRAS drives radioresistance through upregulation of NRF2-53BP1-mediated non-homologous end-joining repairLinlin Yang, Terence M. Williams|Nucleic Acids Research|2021Cited by 68
Targeting oncogenic KRAS in non-small cell lung cancer with EGFR aptamer-conjugated multifunctional RNA nanoparticlesLinlin Yang, Terence M. Williams|Molecular Therapy — Nucleic Acids|2023Cited by 24
Improved Targeting and Safety of Doxorubicin through a Novel Albumin Binding Prodrug ApproachYang Liu, Terence M. Williams|ACS Omega|2023Cited by 7
JNTX-101, a novel albumin-encapsulated gemcitabine prodrug, is efficacious and operates via caveolin-1-mediated endocytosisTiantian Cui, Terence M. Williams|Molecular Therapy — Oncolytics|2023Cited by 6
KRAS-induced STN1 (OBFC1) promotes proper CTC1–STN1–TEN1 complex-independent DNA double-strand break repair and cell cycle checkpoint maintenance in pancreatic cancerChangxian Shen, Terence M. Williams|Nucleic Acids Research|2025Cited by 2